Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.

Cancer biomarkers : section A of Disease markers - 1 Jan 2010

Yeh Chen-Hsiung, Abdool Adam, Bruey Jean-Marie

Abstract excerpt

In targeted therapy using tyrosine kinase inhibitors (TKIs), measurement of TK activities could be beneficial for diagnosis, identification of potential responders, and monitoring treatment efficacy. Here we evaluated the utility of measuring circulating TK (cTK) activity directly from plasma in leukemia patients positive for the BCR-ABL1. Plasma cTK activity was measured from 46 patients with newly diagnosed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Enzyme Assays
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Jurkat Cells

Share to K562 Cells

Share to Proto-Oncogene Proteins c-abl

Share to STAT5 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 21694468
DOI: 10.3233/CBM-2010-0193
PMCID: PMC12922890

Genes

ABL1
BCR
CRKL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.PMID 21694468Read ↗

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.Semantic proximity Read ↗

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.Semantic proximity Read ↗

A novel peptide biosensor for screening ABL1 activity in vitro: a challenge for precision therapy in BCR-ABL1 and BCR-ABL1 like leukemias.Semantic proximity Read ↗

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLSemantic proximity Read ↗

Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.Semantic proximity Read ↗

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.Semantic proximity Read ↗

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.